Peptides GeaGenScript Launches a Series of Beta Amyloid Red Toward Alzheimer’s Disease Research

International contract research organization (CRO) GenScript Corporation has launched a series of beta amyloid peptide fragments targeting Alzheimer’s disease (AD).

This series of peptide products cover both human and rat beta amyloid peptide fragments, selected for research value, particularly their relevance to AD. These peptide fragments cause different biological responses either alone or in combination.

GenScript representatives claim that these synthetic beta amyloid peptides will assist scientists in elucidating the specific roles of beta amyloid peptides in AD’s pathogenic process, possibly helping the development of effective interventions for AD.

The peptides are generated through GenScript's FlexPeptide™ peptide synthesis platform based solely on each fragment’s amino acid sequence information. The platform is equipped with automated synthesizers and covers both liquid and solid phase peptide synthesis (SPPS and LPPS), microwave technology, and proprietary ligation technologies. FlexPeptide™ is also key to GenScript's custom, GMP, and cosmetic peptide production services.

FlexPeptide™'s generalized production protocol requires only the amino acid sequence, giving GenScript a potential to expand its selection of beta amyloid peptides.